Site icon LucidQuest Ventures

Sickle Cell Gene Therapies Ranked by AI Models | LucidScope AI Visibility Audit

Timos Papagatsias
LucidScope_AI_Visibility_Analysis

LucidScope_AI_Visibility_Analysis

Key Findings from the LucidScope AI Visibility Audit  of Casgevy, Lyfgenia, Beam-101 and CS-206

How AI Models Are Shaping Perceptions of Sickle Cell Gene Therapies

Patients, physicians, investors, and industry stakeholders are increasingly turning to AI systems for answers that were once sought through traditional search engines. Questions such as “What is the best sickle cell gene therapy?” or “What comes after Casgevy?” are now being directed to platforms such as ChatGPT, Claude, Gemini, and Perplexity.

The answers these systems provide are shaped by the sources each model retrieves, the evidence it prioritizes, and the way it interprets clinical data. As generative AI becomes part of healthcare information discovery, understanding AI perception is becoming increasingly important for biopharma companies.

To better understand this emerging dynamic, LucidScope conducted an AI Visibility Audit of four sickle cell disease gene therapies: Casgevy, Lyfgenia, Beam-101 / risto-cel, and CS-206. This article summarizes the key findings from the LucidScope AI Visibility Audit. For the complete methodology, model-by-model analysis, source attribution, and strategic recommendations, download the full report: Sickle_Cell_Disease_A_LucidScope_AI_Visibility_Audit .

About the LucidScope AI Visibility Audit

The assessment included:

The objective was not to determine which therapy is clinically superior, but to understand how AI systems currently perceive and communicate information about these therapies.

LucidScope AI Visibility Scorecard for Sickle Cell Gene Therapies

Therapy Share of Voice AI Sentiment Evidence Strength Visibility Outlook
Casgevy 35% Neutral-Positive High Strong
Lyfgenia 30% Mixed High Strong
Beam-101 / risto-cel 18% Positive Emerging Rising
CS-206 16% Neutral Limited Low

Which Sickle Cell Disease Gene Therapies Lead AI Visibility and AI Rankings?

Across all four models, Casgevy was consistently positioned as the most clinically established therapy.

The ranking largely reflected the strength of available evidence. Casgevy combines FDA approval with robust clinical outcomes in both sickle cell disease and transfusion-dependent beta thalassemia. Models frequently referenced data showing that 93.5% of treated sickle cell disease patients remained free of vaso-occlusive crises and that 91.4% of transfusion-dependent beta thalassemia patients achieved transfusion independence.

Lyfgenia was typically ranked second, supported by data showing 88% of patients achieved complete resolution of vaso-occlusive events during the primary evaluation period.

Beam-101 emerged as the leading investigational asset. Models highlighted interim clinical data showing no severe vaso-occlusive crises reported after engraftment during the available follow-up period among treated patients.

CS-206 was consistently ranked last due to its limited evidence base, which currently relies on data from a single patient.

Strategic Implication: Evidence Maturity Drives AI Visibility

AI systems appear to favor therapies supported by clear regulatory milestones, larger datasets, and easily interpretable endpoints. Strong clinical evidence remains the primary driver of AI leadership.

Why Do AI Models Focus on Safety When Evaluating Sickle Cell Disease Gene Therapies?

The most striking finding was the overwhelming emphasis on safety.

Across all models, safety concerns received significantly greater attention than efficacy or commercial adoption. Rather than presenting these therapies as simple one-time cures, AI systems consistently described them as complex, transplant-like procedures involving myeloablative conditioning, prolonged monitoring, and significant treatment burden.

Casgevy was commonly associated with conditioning-related toxicities and discussions around potential off-target CRISPR effects.

Lyfgenia’s AI identity was strongly shaped by its boxed warning for hematologic malignancy and long-term monitoring requirements.

Beam-101 was generally viewed positively but remained associated with treatment-related adverse events reported during development.

Strategic Implication: Class-Wide Safety Narratives Shape AI Perception

Safety narratives can outweigh efficacy narratives. Companies that clearly separate product-specific risk from class-wide treatment burden may be better positioned to influence AI-generated perceptions.

How AI Models Assess Commercial Adoption of Sickle Cell Disease Gene Therapies

The models largely agreed on the commercial story. Across the model outputs, interest in sickle cell gene therapies was generally presented as strong, but adoption was framed as constrained by manufacturing timelines, treatment-center capacity, reimbursement processes, and patient hesitation around conditioning regimens.

Casgevy was consistently portrayed by the models as the commercial leader, supported by references to growing reimbursement coverage and increasing treatment volumes.

Lyfgenia was generally described as commercially viable, but its AI narrative remained influenced by uncertainty following the transition from bluebird bio to Genetix Biotherapeutics.

Beam-101 received some of the most optimistic future-oriented commentary and was frequently framed by AI models as the leading future challenger.

CS-206 was typically described by the models as scientifically interesting but too early to influence near-term market dynamics.

Strategic Implication: AI Models Frame Adoption as an Execution Challenge

AI models do not frame commercial success as a function of efficacy alone. Their outputs suggest that operational execution, reimbursement access, treatment-center capacity, and patient willingness to undergo conditioning are central to how adoption is perceived.

How AI Models Differ in Their Evaluation of Sickle Cell Gene Therapies

Although the models reached similar high-level conclusions, important differences emerged.

GPT-5.5 produced the most structured and evidence-driven responses.

Claude Sonnet 4.6 generated the largest number of citations but occasionally relied on lower-authority sources.

Gemini-3.5-Flash produced the most optimistic assessments and placed greater emphasis on future potential.

Sonar was the most conservative model and was notably skeptical of assets with limited publicly available evidence.

Strategic Implication: Model Choice Can Change the AI Narrative

Model choice itself can influence perception. The same prompt can produce different rankings, narratives, and conclusions depending on which AI system is used.

Which Sources Influence AI Perception of Sickle Cell Disease Gene Therapies?

One of the most important findings was the disconnect between visibility and source influence.

Why Visibility and Influence Are Not the Same

Casgevy achieved the highest overall share of voice, but Beam Therapeutics’ investor website was the single most-cited domain across the analysis. This shows that highly retrievable content can shape AI-generated answers even before a therapy reaches the market.

The analysis also found limited overlap among the sources used by different models. Only a small number of domains were consistently cited across all four systems, reinforcing that AI-generated answers can shift depending on which sources each model retrieves.

Strategic Implication: Retrievability Can Shape AI Perception

Evidence that is difficult for AI systems to retrieve may have less influence than evidence that is highly accessible and frequently cited. In AI visibility, evidence quality matters, but discoverability also shapes perception.

Strategic Implications for Biopharma

The findings suggest that AI visibility is emerging as a measurable component of market perception.

Biopharma companies can no longer assume that generating strong clinical evidence is sufficient. They must also consider whether that evidence is discoverable, understandable, and consistently represented across answer engines.

Three priorities emerge:

  1. Monitor AI visibility alongside traditional share-of-voice metrics.
  2. Ensure authoritative evidence is easy for AI systems to retrieve and interpret.
  3. Differentiate product-specific benefits and risks from broader class narratives.

Organizations that actively manage their AI footprint may be better positioned to influence future conversations among patients, physicians, investors, and policymakers.

Conclusion

Casgevy currently leads AI perception because of its approval status, established clinical evidence, and strong presence across authoritative sources. However, the analysis suggests that leadership in AI-generated narratives is not fixed.

Beam-101 demonstrates how a compelling development story can generate significant visibility before approval. Lyfgenia shows how a single safety concern can dominate AI perception. CS-206 highlights the challenges faced by emerging assets with limited public evidence and inconsistent naming conventions.

The broader lesson extends beyond sickle cell disease. The LucidScope AI Visibility Audit shows that AI perception is becoming an increasingly important layer of healthcare decision-making. As answer engines influence how therapies are discovered, compared, and discussed, organizations must manage not only evidence generation but also evidence visibility and retrievability.

FAQ

Is Casgevy or Lyfgenia better for sickle cell disease?

AI models consistently ranked Casgevy as the most clinically established therapy because of its approval status and breadth of supporting evidence. Lyfgenia was also viewed positively but its AI identity was strongly influenced by its boxed warning for hematologic malignancy.

What is the most promising investigational sickle cell gene therapy?

Across all four models, Beam-101 / risto-cel emerged as the leading investigational challenger and was frequently positioned as the most credible future competitor to approved therapies.

Why does Casgevy lead AI perception but not the citation landscape?

Casgevy achieved the highest share of voice, but Beam Therapeutics’ investor website was the most frequently cited domain in the analysis, highlighting the difference between visibility and source influence.

What is Generative Engine Optimization (GEO) in biopharma?

Generative Engine Optimization (GEO) refers to improving how AI systems retrieve and represent information about a therapy, company, or disease area. For biopharma organizations, GEO involves ensuring that authoritative evidence is highly discoverable, consistently presented, and easy for AI systems to interpret.

Download the Full LucidScope AI Visibility Audit

This article highlights the key findings from the LucidScope AI Visibility Audit.

Download the full report to access:

👉 Download the Full Report: Sickle_Cell_Disease_A_LucidScope_AI_Visibility_Audit

LucidScope helps organizations measure and improve how they are represented across leading AI platforms.

Visit www.lucidscope.ai or contact info@lqventures.com to learn more.

 

Exit mobile version